22 May 2013
Keywords: Teva, XM02, Neutropenia, Biosimilars, Amgen, Neupogen
Article | 02 December 2009
Israel’s Teva Pharmaceutical Industries, better known as a global leader in the generic drug sector, has submitted a Biologics ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 December 2009
21 May 2013
© 2013 thepharmaletter.com